Full Press Release Details
InflaRx receives IND acceptance to proceed
with a Phase IIb Trial with lead candidate IFX-1 in Hidradenitis Suppurativa
Germany, January 9, 2018 - InflaRx N.V. (Nasdaq:IFRX), the biopharmaceutical company developing new therapeutics in
the terminal complement space, today announced the acceptance of their Investigational New Drug (IND) application by the U.S.
Food and Drug Administration (FDA). The open IND will allow InflaRx to conduct a phase IIb study to determine efficacy and safety
of IFX-1, a first-in-class anti-human complement factor C5a antibody, in patients with moderate or severe Hidradenitis Suppurativa.
The randomized, double-blind and placebo-controlled multicenter study is planned to be conducted at approximately 50 sites in
several countries and expected to enroll approximately 175 patients, divided equally into five cohorts. InflaRx intends to
initiate the study in the first quarter of 2018.
Suppurativa (HS) is a painful, chronic and debilitating inflammatory skin disease. The study's primary goal is to evaluate
the dose-response signal of IFX-1 in patients with HS according to the Hidradenitis Suppurativa Clinical Response (HiSCR) at week
16 during the study period. Secondary goals are assessment of further efficacy and patient-reported outcome parameters, as well
as the safety and tolerability of IFX-1. After the placebo-controlled double-blind phase, the study will be extended into an open
label extension phase to assess long-term efficacy and safety. The study will be coordinated by the principal investigator Prof.
Dr. med. Evangelos J. Giamarellos-Bourboulis at the ATTIKON University Hospital in Athens, Greece.
M.D., Chief Medical Officer of InflaRx, said: "With the experience gained from an earlier study of IFX-1 in patients with
Hidradenitis Suppurativa, which demonstrated good safety and encouraging efficacy signals, this trial is designed to find the
optimal dose range as well as to assess long term efficacy and safety of IFX-1. C5a blockade with IFX-1 offers an entirely new
mode of action to treat this disease in which the terminal complement system is highly activated. This study will help us evaluate
a potential new way to treat Hidradenitis Suppurativa."
a first-in-class monoclonal anti-complement factor C5a antibody which completely blocks biological activity in and demonstrates
high selectivity towards its target, C5a in human blood. Thus, IFX-1 leaves the formation of the membrane attack complex (C5b-9)
intact as an important defense mechanism, which is not the case for molecules blocking the cleavage of C5. IFX-1 has been demonstrated
to control the inflammatory response driven tissue and organ damage by specifically blocking C5a as a key "amplifier"
of this response in pre-clinical studies. IFX-1 is the first monoclonal anti-C5a antibody introduced into clinical development
and has, to date, successfully completed three clinical phase II studies. In total, over 150 people have so far been treated with
IFX-1 which was well tolerated. IFX-1 is currently being developed for different inflammatory indications.
(Nasdaq:IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to
discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory
mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in
2007 and has offices in Jena and Munich, Germany. InflaRx is listed on the Nasdaq Global Select Market in the United States
under the trading symbol "IFRX". For further information please visit www.inflarx.com.
Niels C. Riedemann - CEO
Email: info[at]inflarx.de
Tel: +49-3641-508180
Email: inflarx[at]mc-services.eu
Forward Looking Statements:
This press release contains forward-looking statements. All statements
other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "may,"
"will," "should," "expect," "plan," "anticipate," "could,"
"intend," "target," "project," "estimate," "believe," "estimate,"
"predict," "potential" or "continue" and similar expressions. Forward-looking statements appear
in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook,
analyses and current expectations concerning, among other things, our ongoing and planned preclinical development and clinical
trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates,
our intellectual property position, our ability to develop commercial functions, expectations regarding clinical trial data, our
results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry
in which we operate, the trends that may affect the industry or us and the risks uncertainties and other factors described under
the heading "Risk Factors" in InflaRx's periodic filings with the Securities and Exchange Commission. These statements
speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors
that may cause our actual results, performance or achievements to be materially different from any future results, performance
or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you
should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking
statements, even if new information becomes available in the future, except as required by law.